Dealroom：2025年TechBiox人工智能药物发现报告（英文版）

After years of proving that data, computation, and biology can accelerate discovery, TechBio companies are now scaling. The era of theory is giving way to execution: platforms deliver pipelines, automation drives reproducibility, and partnerships transition from pilots to multi-step agreements. AI-discovered drug candidates are no longer confined to research, they are now actively advancing into clinical development.